Company intelligence / Profile preview

Guangzhou JOYO Pharma

Guangzhou, Guangdong, Chinaoa.joyopharma.com ↗

Ownership: Private
Development stage: Other

Overview

Guangzhou JOYO Pharma is currently running multiple Phase 1–3 trials. Its small molecule drug Sufenidone has reached Phase 3 for idiopathic pulmonary fibrosis. WXFL10030390 (WX390), a PI3K-mTOR dual inhibitor, is in Phase 1/2 and Phase 2 studies for solid tumors and lymphoma with encouraging activity and tolerable toxicity. Sudapyridine (WX-081) is in Phase 3 for pulmonary tuberculosis. JYP-0061 has reached Phase 2 for dermatitis, atopic, and neuromyelitis optica, and Phase 1 for rheumatoid arthritis[1][2][3][5].

Therapeutic areas: ImmunologyInfectious DiseasesDermatologyPulmonologyOncologyNeurology
Modalities: Small moleculeMolecular glue
Industry: Biotech

Drug pipeline

5 assets

sudapyridine

4 more assets in the full pipeline.

Partnerships

Shanghai Jiadan Pharmaceutical Technology Co., LtdErasca

Beyond the preview

Go deeper on Guangzhou JOYO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou JOYO Pharma.